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ABSTRACT 
Background: The nootropic or simply known as smart drug is a common term given to any 
compound that is responsible for enhancing mental capability or performance. Alzheimer's 
disease is characterized clinically by lose of cognitive abilities and pathologically by two 
hallmark lesions, neurofibrillary tangles and senile plaques. It is unfortunate that AD has no 
cure yet. In this review attempt has been made to elucidate the general views on AD pathogenic 
hypotheses and common nootropics being used in AD research. Methods: Articles from 
credible scientific data bases such as Sciencdirect, Scopus Pubmed, and Google scholar were 
searched and retrieved using keywords nootropics', Alzheimer's disease', amyloid beta 
hypotheses', tau hypotheses', cholinergic hypotheses', oxidative stress' and cognitive 
impairments'. Results: The nootropics act as Ca-channel blockers, AChE inhibitors, glysine 
antagonists, antioxidants, serotonergic, dopaminergic and glutamic acid receptors antagonists. 
Conclusion: Based on the available literature searched, there is no doubts the nootropics are 
attenuating cognitive deficits in both preclinical and clinical studies on AD. 
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